Merck discontinues antibiotic Recarbrio in US

Merck has stopped manufacturing and marketing Recarbrio, an antibiotic that targeted multidrug-resistant infections.  The FDA approved Recarbrio (cilastatin sodium, imipenem and relebactam) in July 2019 for adults with complicated urinary tract infections or complicated intra-abdominal infections who have limited or no treatment alternatives. About a year later, Recarbrio was also indicated for hospital-acquired bacterial pneumonia […] The post Merck discontinues antibiotic Recarbrio...